Sign in Subscribe
Pharmaceutical industry

Chiron Corp. Acquires Exclusive Rights to Cerubidine

Strategic Insights

— 1 min read

Chiron Corp., a biotechnology company headquartered in Emeryville, California, has announced the acquisition of exclusive rights to Cerubidine (daunorubicin hydrochloride) for injection, a chemotherapeutic product for the treatment of certain leukemias. The company has partnered with Ben Venue Laboratories to manufacture and distribute the product, which will be sold under the Cerubidine brand name. Chiron's vice president of marketing and sales, Edward Kenney, stated that the acquisition represents a significant addition to the company's line of oncology products, including Proleukin and Aredia.

Key Takeaways:

  • Chiron Corp. has acquired exclusive rights to Cerubidine (daunorubicin hydrochloride) for injection from Wyeth-Ayerst Laboratories.
  • The product will be manufactured and distributed by Chiron Therapeutics and Ben Venue Laboratories.
  • Wyeth-Ayerst will assign all trademark and technology rights to Cerubidine to the joint venture.
  • Chiron Therapeutics and Ben Venue already have FDA licenses to manufacture and sell daunorubicin.
  • The acquisition represents a significant addition to Chiron's line of oncology products, including Proleukin and Aredia.
  • Edward Kenney, vice president of marketing and sales, emphasized the importance of Cerubidine in the treatment of leukemia.
  • Chiron Therapeutics markets Proleukin and Aredia in the United States and Europe.

Statistics:

  • Chiron Corp. is a biotechnology company headquartered in Emeryville, California.
  • Chiron Therapeutics markets a line of chemotherapeutic products, including Proleukin and Aredia.
  • The joint venture between Chiron Therapeutics and Ben Venue Laboratories has produced and inventoried significant quantities of daunorubicin.
  • Chiron Therapeutics and Ben Venue already have FDA licenses to manufacture and sell daunorubicin.

Sources:

  • Business Wire, "Chiron Corp. Acquires Exclusive Rights to Cerubidine" (March 27, 1995)
  • Chiron Corp., press release, "Chiron Corp. Acquires Exclusive Rights to Cerubidine" (March 27, 1995)

Read more